[1]Chang KC, Yew WW, Chan RC.Rapid assays for fluoroquino-lone resistance in Mycobacterium tuberculosis:a systematic review and meta-analysis. J Antimicrob Chemother,2010,65(8):1551-1561.[2]Vilemagne B, Crauste C, Flipo M, et al. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem, 2012,51:1-16.[3]Fillion A1, Aubry A, Brossier F, et al.Impact of fluoroquino-lone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother,2013,57(9):4496-4500.[4]Ahmad Z, Tyagi S, Minkowski A, et al. Contribution of mo-xifloxacin or levofloxacin in second-line regimens with or wi-thout continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med,2013,188(1):97-102.[5]World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.Geneva: World Health Organization, 2011.[6]Koh WJ, Lee SH, Kang YA, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2013,188(7):858-864.[7]Segreti J, Jones RN, Bertino JS Jr. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. J Ocul Pharmacol Ther, 2012,28(1):3-11.[8]Francis J. Curry National Tuberculosis Center, California Department of Public Health. 耐药结核病临床医生使用指南. 2版. 李亮,译. 北京:中国疾病预防控制中心结核病防治临床中心,中华医学会结核病学分会,世界卫生组织结核病研究培训合作中心,2008:49-66.[9]Mpagama SG, Ndusilo N, Stroup S, et al. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother, 2014,58(2):782-788.[10]Guerrini V, De Rosa M, Pasquini S, et al. New fluoroquinolones active against fluoroquinolones-resistant Mycobacterium tuberculosis strains. Tuberculosis (Edinb), 2013,93(4):405-411.[11]Jo KW, Lee SD, Kim WS, et al.Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2014,18(1):39-43.[12]Lemos AC, Matos ED. Multidrug-resistant tuberculosis. Braz J Infect Dis, 2013,17(2):239-246.[13]Volmink J, Garner P. WITHDRAWN: interventions for promoting adherence to tuberculosis management. Cochrane Database Syst Rev, 2007,18(4):CD000010.[14]Gao CH, Yu LS, Zeng S, et al.Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns. Ther Clin Risk Manag, 2014,10:217-227.[15]孙雯雯,吴福蓉,肖和平,等. 强化期含左氧氟沙星方案保守治疗脊柱结核的近期疗效分析. 中国防痨杂志,2013,35(10):840-842.[16]Patel SN, McGeer A, Melano R, et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother,2011,55(8):3703-3708.[17]Emilio D, 刘宇红, Catharina VW, 等.全球结核病控制:过去、现在和未来. 结核病与肺部健康杂志,2013,2(3):143-149.[18]Lee J, Lee CH, Kim DK, et al. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med, 2011,26(2):153-159.[19]Maranetra KN. Quinolones and multidrug-resistant tuberculosis. Chemotherapy,1999,45(Suppl 2): 12-18.[20]Jiang RH, Xu HB, Li L. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. Int J Antimicrob Agents,2013,42(1):36-41.[21]Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf, 2013,12(4):497-505.[22]Johnson JL, Hadad DJ, Boom WH,et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis, 2006, 70(6):605-612. |